Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBRUTINIB vs CALQUENCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
FDA-approved: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,FDA-approved: Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Off-label: Treatment of Waldenström macroglobulinemia,Off-label: Treatment of marginal zone lymphoma
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
100 mg orally twice daily.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism by CYP2D6. The active metabolite is PCI-45227.
Primarily metabolized by CYP3A4 to form acalabrutinib M27 (active metabolite). Minor routes include glutathione conjugation and hydrolysis. Acalabrutinib is also a substrate of CYP3A5 and to a lesser extent CYP2C8.
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Fecal (77%), renal (15% as unchanged drug and metabolites).
97.3% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
97% bound to plasma proteins (albumin and alpha-1 acid glycoprotein).
Apparent Vd is approximately 10,000 L (large), indicating extensive tissue distribution.
Approximately 10 L/kg, indicating extensive tissue distribution.
Oral bioavailability is 62% (range 52-74%) under fasted conditions; food increases AUC by 1.7-fold.
Oral bioavailability is approximately 70%; absorption is unaffected by food.
No dose adjustment required for creatinine clearance ≥25 m L/min. Insufficient data for patients with Cr Cl <25 m L/min or on dialysis.
No dose adjustment required for Cr Cl >=30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg once daily.
Child-Pugh class A: No adjustment. Child-Pugh class B: Reduce dose to 280 mg once daily. Child-Pugh class C: Reduce dose to 140 mg once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: avoid use.
Adolescents (≥12 years): 420 mg once daily; weight-based dosing not established. For pediatric patients <12 years: not approved.
Not established for pediatric patients.
No specific dose adjustment; monitor for cardiac adverse events (atrial fibrillation, hypertension) and bleeding risk due to higher incidence in elderly.
No specific dose adjustment beyond standard monitoring for toxicity.
Hemorrhage: Fatal bleeding events have occurred in patients receiving ibrutinib. Major hemorrhage (e.g., gastrointestinal, intracranial) has been reported. Monitor for signs of bleeding. Consider benefit-risk of holding ibrutinib for 3-7 days pre- and post-surgery depending on procedure.
None
Hemorrhage: Increased risk of bleeding, especially in patients on anticoagulants or antiplatelet agents. Avoid concomitant use of warfarin.,Infections: Fatal and serious infections (including bacterial, viral, fungal) have occurred. Consider prophylaxis in patients at increased risk.,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia have occurred. Monitor blood counts monthly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor cardiac function, especially in patients with cardiac risk factors.,Hypertension: New-onset or worsening hypertension has been reported. Monitor blood pressure and manage appropriately.,Second primary malignancies: Other malignancies (including skin cancers) have occurred. Perform skin cancer monitoring.,Tumor lysis syndrome: Risk is increased in patients with high tumor burden. Monitor and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have been observed. Monitor hepatic function.
Hemorrhage: Fatal and serious bleeding events have occurred. Monitor for signs of bleeding, especially in patients on antithrombotic agents or with thrombocytopenia. Consider benefit-risk of holding acalabrutinib for 3-7 days pre- and post-surgery.,Infections: Fatal and serious infections, including opportunistic infections, have occurred. Monitor for signs and symptoms of infection and treat promptly.,Cytopenias: Grade 3 or 4 cytopenias (neutropenia, anemia, thrombocytopenia) can occur. Monitor complete blood counts regularly.,Second primary malignancies: Including skin cancers and other solid tumors. Advise patients to use sun protection.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for cardiac arrhythmias and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have occurred. Monitor liver function tests.,Interstitial lung disease (ILD): Cases of ILD/pneumonitis have occurred. Monitor for pulmonary symptoms and manage as indicated.
Concomitant use with warfarin or other vitamin K antagonists (increased bleeding risk) is not recommended but not absolutely contraindicated; use with caution.,Severe hepatic impairment (Child-Pugh class C) – use not recommended.
None (no absolute contraindications). Avoid use in patients with severe hepatic impairment (Child-Pugh class C) due to lack of data; use with caution in moderate impairment (Child-Pugh class B).
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they can increase drug levels and toxicity. Take with a full glass of water; may be taken with or without food but avoid high-fat meals as they may increase absorption variability.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit (which contain strong CYP3A4 inhibitors) during treatment with CALQUENCE. No other specific food restrictions are required. The drug can be taken with or without food.
Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotoxic at exposures below the human AUC at the clinical dose. There are no adequate and well-controlled studies in pregnant women. Use during first trimester may cause structural abnormalities; second and third trimester use may impair fetal B-cell development and hematopoiesis.
Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of acalabrutinib to pregnant rats during organogenesis resulted in embryofetal mortality and malformations at exposures below the clinical exposure at the recommended human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester exposure poses highest risk; second and third trimesters also carry risk of fetal toxicity.
No data on presence in human milk, effects on breastfed infant, or milk production. Ibrutinib and its active metabolite are detected in rat milk at concentrations higher than maternal plasma. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after last dose.
No data are available on the presence of acalabrutinib or its metabolites in human milk, effects on the breastfed child, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with CALQUENCE and for at least 2 weeks after the last dose. M/P ratio is unknown.
No specific dosing adjustments for pregnancy have been established due to lack of human pharmacokinetic data. Pregnancy may alter drug clearance via increased hepatic metabolism and renal function; however, no dose adjustment recommendations can be made. Use only if maternal benefit outweighs fetal risk, with consideration of therapeutic drug monitoring if available.
No specific dose adjustments are recommended for pregnancy due to lack of data on pharmacokinetic changes. However, because of potential alterations in drug metabolism and clearance during pregnancy, therapeutic drug monitoring may be considered if available. The manufacturer does not provide guidance for dose adjustment in pregnant women; use during pregnancy should be avoided unless clearly needed.
Monitor for atrial fibrillation (occurrence ~6-16%, higher risk in elderly). Obtain baseline ECG and monitor for bleeding due to antiplatelet effect (avoid concurrent anticoagulants unless necessary). Check for tumor lysis syndrome risk, especially in high tumor burden. Ibrutinib is a strong CYP3A4 inhibitor; avoid co-administration with sensitive CYP3A4 substrates or adjust doses. Monitor for hypertension and myelosuppression.
CALQUENCE (acalabrutinib) is a selective BTK inhibitor used in B-cell malignancies. It has fewer off-target effects than ibrutinib, particularly less atrial fibrillation and bleeding. Monitor for atrial fibrillation, hypertension, infections (especially respiratory), and bleeding events. Drug interactions with CYP3A4 inducers/inhibitors are significant; avoid concurrent use with strong CYP3A4 inhibitors or inducers. May need to hold for 3 days before and after procedures due to bleeding risk. Consider antiviral prophylaxis for herpes zoster in high-risk patients. Do not crush or break capsules; swallow whole with water. Dose adjustment for severe hepatic impairment (Child-Pugh C) is required.
Take exactly as prescribed; do not miss doses or stop without consulting your doctor.,Take capsules whole with water at the same time each day; do not open or chew.,Avoid grapefruit, Seville oranges, and starfruit during treatment.,Report any unusual bleeding, bruising, or black/tarry stools immediately.,Contact your healthcare provider if you experience irregular heartbeat, chest pain, or dizziness.,Use effective contraception during treatment and for 1 month after last dose.,Do not take with strong CYP3A4 inhibitors unless directed; avoid St. John's wort.
Take CALQUENCE exactly as prescribed, usually twice daily with or without food. Swallow capsules whole; do not open, break, or chew them.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while taking this medication, as they can affect how the drug works.,Tell your healthcare provider about all medications you take, including prescription, over-the-counter, vitamins, and herbal products, especially St. John's wort.,CALQUENCE can increase your risk of serious infections, bleeding problems, and heart rhythm issues. Report any signs of infection (fever, chills), unusual bruising or bleeding, palpitations, or dizziness.,Do not stop taking CALQUENCE without consulting your healthcare provider. If you miss a dose, take it as soon as you remember unless it is less than 6 hours until your next dose; then skip the missed dose.,Women who are pregnant or breastfeeding should not take CALQUENCE. Effective contraception is needed during treatment and for 1 week after the last dose.,Keep CALQUENCE in the original container at room temperature (68°F to 77°F), away from moisture and light.
"Ibrutinib, a potent Bruton's tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. Saquinavir, a protease inhibitor and potent CYP3A4 inhibitor, may significantly increase the plasma concentration of ibrutinib by reducing its clearance. This elevation in ibrutinib exposure can potentiate its adverse effects, including myelosuppression, atrial fibrillation, hemorrhage, and infections, necessitating dose adjustment or alternative therapy."
"Ibrutinib, a Bruton's tyrosine kinase inhibitor, can inhibit organic anion transporters (OATs), leading to decreased renal clearance of sulfamethoxazole. This results in increased plasma concentrations of sulfamethoxazole, potentially enhancing its therapeutic effects and risk of dose-dependent toxicities such as hypersensitivity reactions, hematologic abnormalities, and crystalluria. Patients may experience prolonged QT interval or decreased renal function due to sulfamethoxazole accumulation."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBRUTINIB vs CALQUENCE, answered by our medical review team.
IBRUTINIB is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.. CALQUENCE is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBRUTINIB and CALQUENCE depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBRUTINIB is: Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.. The standard adult dose of CALQUENCE is: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBRUTINIB and CALQUENCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBRUTINIB is classified as Category D/X. Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotox. CALQUENCE is classified as Category C. Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.